Feed OGEN
OG

Oragenics, Inc.

OGEN · AMEX

$0.49 -3.34% (-$0.02)
1M -9.83%
Market Cap $2.27M
P/E Ratio -
Div. Yield -
ROE 144.23%

Bulios Fair Price

$0.58

19.2% upside

Trenutna cena

$0.49

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica OGEN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 0.62x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 13.98%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 279.54%
Asset turnover 0.00x
ROE 144.23%
Debt
69 /100
Low
Debt/Equity 0.00x
Int. coverage -551.49x
Current ratio 3.01x
Stability
21 /100
Unstable
Beta 1.25x
Profitable years 0
EPS volatility 134.39%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o OGEN
Online

O podjetju

Oragenics Inc. (OGEN) is a biotechnology company focused on the development and commercialization of therapeutic and diagnostic products in the field of medical microbiomics. With a product portfolio including drugs and diagnostic tests targeting the treatment of infectious diseases and improvement of microbiome health, Oragenics plays a key role in research and development of new therapeutic and diagnostic approaches. The company focuses on utilizing knowledge of the microbiome to discover new therapeutic targets and diagnostic markers, which may lead to the development of more effective drugs and diagnostic tools. With growing awareness of the importance of the microbiome for human health and the need for innovative therapeutic methods and diagnostic tests, Oragenics has the potential for further growth and development. OGEN shares could be suitable for investors seeking exposure in the biotechnology sector with a focus on microbiome and innovative therapeutic and diagnostic approaches.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Janet Huffman

Employees

3

Headquarters

Lakewood Ranch

Prihajajoči dogodki

16 NOV.

Earnings

Upcoming earnings report

65d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.